A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04194775 |
Recruitment Status :
Active, not recruiting
First Posted : December 11, 2019
Last Update Posted : November 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hepatocellular Carcinoma | Drug: Nofazinlimab (CS1003)+Lenvatinib Drug: Nofazinlimab (CS1003) Placebo+Lenvatinib | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 534 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Multi-Center, Double-Blind, Randomized, Phase III Study to Investigate the Efficacy and Safety of Nofazinlimab (CS1003) in Combination With Lenvatinib Compared to Placebo in Combination With Lenvatinib as First-Line Therapy in Subjects With Advanced Hepatocellular Carcinoma (HCC) |
Actual Study Start Date : | December 13, 2019 |
Estimated Primary Completion Date : | June 30, 2023 |
Estimated Study Completion Date : | June 30, 2023 |

Arm | Intervention/treatment |
---|---|
Experimental: Nofazinlimab (CS1003) |
Drug: Nofazinlimab (CS1003)+Lenvatinib
Nofazinlimab (CS1003), intravenous (i.v.) administration every 21 days; Lenvatinib oral administration, once daily |
Placebo Comparator: Nofazinlimab (CS1003) placebo |
Drug: Nofazinlimab (CS1003) Placebo+Lenvatinib
Nofazinlimab (CS1003) Placebo, i.v. administration every 21 days ; Lenvatinib oral administration, once daily |
- Progression-free survival (PFS) evaluated by the Blinded Independent Central Review Committee (BICR) based on Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 [ Time Frame: up to approximately 42 months ]
- Overall survival (OS) [ Time Frame: up to approximately 42 months ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion criteria
- Age ≥18 years on the day of signing informed consent-(For Taiwan, the lower limit of age is 20 years).
- Subjects with unresectable advanced HCC, that is not eligible for surgery and/or locoregional therapy (Stage B or C based on Barcelona Clinic Liver Cancer [BCLC] staging system, and meets either one of the following criteria: 1) histologically or cytologically confirmed diagnosis of HCC, 2) clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria. Patients without cirrhosis require histological confirmation of diagnosis.
- With at least one measurable lesion can be assessed
- Eastern Cooperative Oncology Group performance status (ECOG PS) 0 or 1.
- Life expectancy ≥ 3 months.
- Child-Pugh A
- No prior systemic treatment for advanced HCC
- Subjects with hepatitis B virus (HBV) infection, # are willing to continue receiving antiviral treatment while on study.
-
Subjects have adequate organ and marrow function. Female subjects with childbearing potential must have negative serum pregnancy test result at screening. Female subjects with childbearing potential, and male subjects and their female partners with childbearing potential must agree to use an contraceptive method(s) from the day of signing informed consent form (ICF), during the study and till at least 6 months after the last dose of study treatment.
Exclusion criteria
- Fibrolamellar-HCC, sarcomatoid, cholangiocellular carcinoma or mixed cholangiocarcinoma and HCC.
- A prior bleeding event due to esophageal within 6 months or other gastrointestinal bleeding events within 28 days prior to screening.
- Malabsorption syndrome or inability to take oral medication due to other causes.
- HBV and HCV co-infection.
- Investigator evaluates to increase the drug related risk caused by enrolling subjects in trial and taking study drug, or any serious or uncontrolled systematic disease that confound the drug absorption or the study outcome, e,g diabetes mellitus, hypertension, rheumatoid arthritis, major cardiovascular disease and so on.
- Surgery or locoregional therapy for palliative purpose within 4 weeks prior to study treatment.
- History of other malignancy(ies) in the past 5 years, except for malignant disease treated with curative intent and without active disease.
- Known history of human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS).
- Current or prior use of systemic corticosteroid (> 10 mg/day prednisone or equivalent) or other immunosuppressive medication within 14 days prior to the first dose of study treatment.
- History of bone marrow transplantation or organ transplantation.
- History of anaphylaxis or hypersensitivity to any ingredient of the investigational product.
- Any contraindication of lenvatinib.
- Known history of drugs abuse that would interfere with cooperation with the requirements of the trial.
- Pregnant or lactating female subjects.
- History of psychiatric disease that would interfere with cooperation with the requirements of the trial; lack of or with restricted physical capability.
- QTc interval > 470 msec (as calculated with Fridericia's formula) at screening electrocardiogram (ECG);
- Any condition that would in the investigator's judgment, prevent the subject from participating in this study.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04194775
United States, California | |
Southern California GI and Liver Centers | |
Coronado, California, United States, 92118 | |
Inland Empire Liver Foundation | |
Rialto, California, United States, 92377 | |
United States, Maryland | |
Mercy Medical Center | |
Baltimore, Maryland, United States, 21202 | |
United States, Massachusetts | |
UMass Memorial Health | |
Worcester, Massachusetts, United States, 01655 | |
United States, New York | |
Stony Brook University Hospital | |
Stony Brook, New York, United States, 11794 | |
China, Shanghai | |
Zhongshan Hospital | |
Shanghai, Shanghai, China, 201203 |
Responsible Party: | CStone Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT04194775 |
Other Study ID Numbers: |
CS1003-305 |
First Posted: | December 11, 2019 Key Record Dates |
Last Update Posted: | November 10, 2022 |
Last Verified: | October 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
Carcinoma Carcinoma, Hepatocellular Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Adenocarcinoma Liver Neoplasms Digestive System Neoplasms |
Neoplasms by Site Digestive System Diseases Liver Diseases Lenvatinib Antineoplastic Agents Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |